Pregabalin

證據等級: L5

預測適應症: 10 個

Pregabalin: From Neuropathic Pain to Tendinitis

One-Sentence Summary

Pregabalin is a gabapentinoid internationally established for neuropathic pain, epilepsy (adjunct therapy), fibromyalgia and generalised anxiety disorder — though this evidence pack itself does not contain the original-indication record (data gap) and the drug is currently not TGA-registered in Australia. The TxGNN model predicts it may be effective for Tendinitis, but this direction is currently supported by only 0 clinical trials and 6 publications, most of which are indirect (post-operative analgesia after rotator cuff repair, or unrelated case reports).

Quick Overview

Item	Content
Original Indication	Not available in evidence pack (Pregabalin is internationally indicated for neuropathic pain, epilepsy adjunct therapy, fibromyalgia and generalised anxiety disorder)
Predicted New Indication	Tendinitis
TxGNN Prediction Score	99.71%
Evidence Level	L4
Australia Market Status	Not Marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Pregabalin in this evidence pack (Data Gap DG002). Based on known information, Pregabalin binds the α2δ subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release and central/peripheral nerve sensitisation — its efficacy in neuropathic pain conditions is well established. Mechanistically, this pathway could plausibly reduce pain associated with tendon injury, but it has no known action on the actual pathology of tendinitis (inflammation or collagen repair).

Consistent with this, the literature retrieved for this candidate is largely indirect: two RCTs examine perioperative pregabalin as post-operative analgesia after arthroscopic rotator cuff repair (not treatment of tendinitis itself), and the remaining items are case reports or reviews of unrelated nerve-entrapment and tendinopathy topics. No study evaluates pregabalin’s effect on the inflammatory or collagen-repair processes underlying tendinitis. This is reflected in the assigned evidence level of L4 (mechanism/preclinical-level support only) and a “Hold” recommendation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34052386	2022	RCT	Arthroscopy	Perioperative oral pregabalin produced post-operative pain scores equivalent to interscalene brachial plexus block after arthroscopic rotator cuff repair — a peri-surgical analgesia study, not a tendinitis treatment trial.
32839073	2021	RCT	Journal of Orthopaedic Science	Retrospective cohort evaluating pregabalin’s opioid-sparing analgesic effect after arthroscopic rotator cuff repair; evidence on efficacy remains conflicting.
40818536	2025	Review	Arthroscopy	Editorial commentary on diagnosis and surgical treatment of piriformis syndrome; not pregabalin-specific.
41017607	2025	Case Report	Praxis	Case report of fluoroquinolone (ciprofloxacin)-associated tendinopathy/disability; unrelated to pregabalin therapy.
37051935	2023	Case Report	Pain Practice	Case report of posterior femoral cutaneous nerve injury caused by hamstring tendonitis in a marathon runner; does not evaluate pregabalin.
39703364	2024	Preclinical	Advances in Pharmacological and Pharmaceutical Sciences	Rat study of a plant extract (Cissus quadrangularis, not pregabalin) attenuating vincristine-induced peripheral neuropathy.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. (Key warnings, contraindications and drug interaction data for Pregabalin are recorded as data gaps in this evidence pack — DG001, Blocking severity — and were not available for review.)

Conclusion and Next Steps

Decision: Hold

Rationale: The tendinitis prediction sits at evidence level L4 with no supporting clinical trials, and the available literature is indirect (post-operative analgesia after shoulder surgery, or case reports unrelated to pregabalin). No mechanistic pathway links pregabalin to the inflammatory or collagen-repair processes underlying tendinitis, so this candidate does not currently support progression beyond a research hypothesis.

To proceed, the following is needed:

TGA-approved Product Information (PI) — warnings and contraindications (currently a Blocking data gap, DG001)
Detailed mechanism of action data from DrugBank (currently a High-severity data gap, DG002)
Direct preclinical or clinical evidence evaluating pregabalin’s effect on tendon inflammation or collagen repair
Confirmation of a TGA registration/import pathway, as Pregabalin currently has 0 ARTG entries in Australia

Note: Other TxGNN-predicted indications for Pregabalin in this same evidence pack carry substantially stronger evidence than tendinitis — notably osteoarthritis (rank 8, evidence level L2, decision stage S2, “Proceed with Guardrails,” with multiple completed Phase 3/4 RCTs) and migraine disorder (rank 5, evidence level L2, “Research Question,” including paediatric RCTs and a withdrawn adult Phase 3 trial). These may warrant separate, dedicated evaluation reports.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.